Pulmonary Fibrosis News and Research

RSS

3-D imaging of fibroblastic foci may help researchers study disease progression in IPF patients

Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which progressive scarring of the lungs leads to respiratory failure. Lung scarring in IPF takes the form of aggregates of proliferating fibroblasts and myofibroblasts, known as "fibroblastic foci", which deposit collagen and other fibrotic components. These foci are thought to form in response to lung injury.

22 Apr 2016

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.

15 Apr 2016

Complete genetic map of scleroderma opens door for diagnosis and targeted treatment

Scleroderma is an autoimmune disease that affects one out of every 10,000 people in Europe and North America, mostly middle-aged women, and causes death in a high percentage of cases.

11 Apr 2016

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.

4 Apr 2016

VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

VolitionRx Limited today announced preliminary data from a pilot study demonstrating that the Company’s NuQ® blood test detected 86% of subjects with a deadly lung disease, called Idiopathic Pulmonary Fibrosis (IPF).

10 Mar 2016

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body

7 Mar 2016

New international survey provides insights into emotional truths of living with IPF

An international survey of over 500 people living with idiopathic pulmonary fibrosis (IPF) in more than 20 countries worldwide reveals the real-life emotions faced by those with the devastating disease.

1 Mar 2016

Rare Disease Day 2016: Boehringer Ingelheim launches new initiatives to raise awareness of IPF

Boehringer Ingelheim, working with pharmaphorum media, has brought together patients, patient groups and globally renowned clinicians to launch a report into IPF entitled Inspiration - a new initiative dedicated to raising awareness of IPF,1 a rare disease that is relatively unheard of, frequently misdiagnosed and little understood.

1 Mar 2016

UA College of Pharmacy assistant professor developing dry powder inhalers to treat pulmonary diseases

Heidi M. Mansour, PhD, assistant professor in the University of Arizona College of Pharmacy, is working to develop advanced dry powder inhalers to treat and prevent pulmonary diseases.

23 Feb 2016

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.

12 Feb 2016

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB.

5 Jan 2016

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS (Safety and Efficacy ofNintedanib in Systemic SClerosIS) study.

10 Dec 2015

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug) for potential disease modifying treatment of osteoarthritis (OA) of the knee at 2015 American College of Rheumatology Annual Meeting.

4 Nov 2015

IPF-PRO Registry data sheds light on characteristics of people with idiopathic pulmonary fibrosis

Boehringer Ingelheim Pharmaceutical, Inc. today announced initial results of the first 49 people enrolled in the IPF-PRO Registry, which shed light on characteristics of people with IPF at the time of diagnosis.

23 Oct 2015

Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Boehringer Ingelheim and BioMed X announced today that they have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD).

21 Sep 2015

Hermansky-Pudlak syndrome can cause debilitating lung disease in Puerto Ricans

A hereditary condition called Hermansky-Pudlak syndrome (HPS) can cause bleeding problems, low vision, albinism and, in some patients, a debilitating lung disease.

21 Sep 2015

Ex-vivo lung perfusion technique can reduce risk of transplant rejection

University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection.

15 Sep 2015

Simple stem cell production method shows promise in mice for treating IPF

In a small pilot study, researchers from North Carolina State University have demonstrated a rapid, simple way to generate large numbers of lung stem cells for use in disease treatment. This method of harvesting and growing a patient's own lung stem cells shows promise in mice for treating idiopathic pulmonary fibrosis (IPF), and could one day provide human IPF sufferers with an effective, less invasive method of treatment for their disease.

10 Sep 2015

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

The Pulmonary Fibrosis Foundation and Veracyte, Inc. announced that the organizations are partnering on a U.S. patient survey to advance understanding of patients' diagnostic experiences with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF).

27 Aug 2015